Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBITDA Margin (2019 - 2023)

Benitec Biopharma has reported EBITDA Margin over the past 5 years, most recently at 66257.14% for Q2 2023.

  • Quarterly results put EBITDA Margin at 66257.14% for Q2 2023, changed N/A from a year ago — trailing twelve months through Mar 2024 was 309628.57% (down 28122416.0% YoY), and the annual figure for FY2023 was 25529.33%, down 87454.0%.
  • EBITDA Margin reached 66257.14% in Q2 2023 per BNTC's latest filing, down from 8059.26% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 6157.14% in Q2 2020 and bottomed at 393300.0% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 10725.0% (2020), compared with a mean of 80603.12%.
  • The largest annual shift saw EBITDA Margin plummeted -38257500bps in 2021 before it soared 38599167bps in 2022.
  • Over 5 years, EBITDA Margin stood at 2277.92% in 2019, then plummeted by -13263bps to 304400.0% in 2020, then surged by 94bps to 19512.0% in 2021, then tumbled by -104bps to 39792.86% in 2022, then plummeted by -67bps to 66257.14% in 2023.
  • Business Quant data shows EBITDA Margin for BNTC at 66257.14% in Q2 2023, 8059.26% in Q1 2023, and 39792.86% in Q4 2022.